Argos Therapeutics Raises $5.0 Million in Debt Financing.DURHAM, N.C. -- Argos Therapeutics today announced that it has raised $5.0 million in a three-year debt financing arrangement with Silicon Valley Bank and Oxford Finance Corporation. The financing will be used primarily to fund the Company's three ongoing clinical trials in renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. (Phase 2), chronic lymphocytic leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. (Phase 1/2) and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. (Phase 1), utilizing its personalized RNA-loaded dendritic cell-based immunotherapy ("Arcelis") technology for cancer and HIV. "These resources provide Argos with additional flexibility with respect to financing the advancement of our pipeline of personalized immunotherapy candidates," said John Bonfiglio, Ph.D., President and CEO of Argos Therapeutics. "In 2007 we expect to report durable response data from our chronic lymphocytic leukemia trial, as well as immune response and safety data from our HIV trial." About Argos Therapeutics, Inc. Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient's disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company's "Arcelis" technology, trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com Argos is a private biotechnology company headquartered in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , NC. The Company has clinical trial programs in cancer and human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company Kirin Brewery Company, Ltd. (麒麟麦酒株式会社 , Limited. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion